Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2111456 Target Snapshot

Vasopressin V1 receptor · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
60Compounds
8Assays
1Approved Drugs
33.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Vasopressin V1 receptor shows approved-linked disease relevance led by hepatorenal syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P37288. Start with hepatorenal syndrome, then reuse UniProt P37288 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hepatorenal syndrome, then reuse UniProt P37288 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
hepatorenal syndrome

Vasopressin V1 receptor shows approved-linked disease relevance led by hepatorenal syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with hepatorenal syndrome because it currently carries approved-linked support. Linked drugs include TERLIPRESSIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Vasopressin V1 receptor as ChEMBL target CHEMBL2111456, mapped to UniProt P37288. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Vasopressin V1 receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2111456
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P37288
Vasopressin V1a receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Vasopressin V1 receptor is the right protein anchor across sources, using UniProt P37288 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hepatorenal syndrome is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameVasopressin V1 receptor
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP37288
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelVasopressin V1a receptor
UniProt AccessionP37288
Component TypeProtein
Sequence Length418 aa

Vasopressin V1a receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Vasopressin V1 receptor, mapped to UniProt P37288. ChEMBL maps the protein component as Vasopressin V1a receptor. Sequence length is 418 aa.

Mapped IDP37288
Review nameVasopressin V1 receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Vasopressin V1 receptor shows approved-linked disease relevance led by hepatorenal syndrome. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hepatorenal syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugTERLIPRESSIN
Approved-linked Approved
kidney failure
1 linked drug · 1 direct · 1 efficacy
Linked drugTERLIPRESSIN
Approved-linked Approved
Renal insufficiency
1 linked drug · 1 direct · 1 efficacy
Linked drugTERLIPRESSIN
Late clinical Phase III
cirrhosis of liver
1 linked drug · 1 direct · 1 efficacy
Linked drugTERLIPRESSIN
Late clinical Phase III
Hemoptysis
1 linked drug · 1 direct · 1 efficacy
Linked drugTERLIPRESSIN
Late clinical Phase III
hemorrhage
1 linked drug · 1 direct · 1 efficacy
Linked drugTERLIPRESSIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hepatorenal syndrome because it currently carries approved-linked support. Linked drugs include TERLIPRESSIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehepatorenal syndrome
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
Assay Mix

Activity Type Distribution

IC5032.0
KI1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL430083 8.52 IC50 3.0 Preclinical
CHEMBL367323 8.4 IC50 4.0 Preclinical
CHEMBL368354 8.3 IC50 5.0 Preclinical
CHEMBL177248 8.3 IC50 5.0 Preclinical
CHEMBL368353 8.0 IC50 10.0 Preclinical
CHEMBL413748 8.0 IC50 10.0 Preclinical
CHEMBL368818 7.3 IC50 50.0 Preclinical
CHEMBL368462 7.3 IC50 50.0 Preclinical
CHEMBL177885 7.3 IC50 50.0 Preclinical
CHEMBL369150 7.22 IC50 60.0 Preclinical
Distribution

pChEMBL Value Distribution

2
5.0
6
5.5
9
6.0
3
6.5
4
7.0
0
7.5
5
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

8
Total Assays
27
Tested Compounds
2
Assay Types
Binding — 7 assays, 27 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 5 0 —
assay format 2 27 6.7
Functional — 1 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 3 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine